Novel cellular and post-genomic technologies in the treatment of glioblastoma multiforme (Review)

Bryukhovetskiy,Igor; Bryukhovetskiy,Andrey; Khotimchenko,Yuri; Mischenko,Polina

doi:10.3892/or.2015.4404

Novel cellular and post-genomic technologies in the treatment of glioblastoma multiforme (Review)

Authors:
- Igor Bryukhovetskiy
- Andrey Bryukhovetskiy
- Yuri Khotimchenko
- Polina Mischenko
View Affiliations

Affiliations: Laboratory of Molecular and Cellular Neurobiology, School of Biomedicine, Far Eastern Federal University, Vladivostok 690091, Russian Federation, School of Biomedicine, Far Eastern Federal University, Vladivostok 690091, Russian Federation
Published online on: November 6, 2015 https://doi.org/10.3892/or.2015.4404
Pages: 639-648

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Glioblastoma multiforme (GBM) is one of the most aggressive brain tumors. The majority of modern treatment methods for GBM are not sufficiently effective with a median survival varying from 9 to 14 months. One of the main reasons for the therapeutic resistance of GBM is attributed to cancer stem cells. Pharmaceuticals that can effectively eliminate cancer stem cells do not exist. Experimentally, we have shown that cancer stem cells can be specifically affected to arrest adhesion, proliferation and migration, and other key functions. The main target of this therapy involves membrane intracellular signaling pathways of cancer stem cells that are not subject to neoplastic transformation. An effect on such a complex target requires the development of innovative biotechnological approaches. The research analysis of modern approaches towards creating biomedical drugs for treating cancer stem cells of glioblastoma multiforme is based on advances in the latest cellular and post-genomic technologies. The combination of targeted therapy with regulation of the key functions of cancer stem cells using cell systems with a remodeled proteome is suggested.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
3	Smith RA, Manassaram-Baptiste D, Brooks D, Doroshenk M, Fedewa S, Saslow D, Brawley OW and Wender R: Cancer screening in the United States, 2015: A review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin. 65:30–54. 2015. View Article : Google Scholar : PubMed/NCBI
4	Louis DN, Perry A, Burger P, Ellison DW, Reifenberger G, von D eimling A, Aldape K, Brat D, Collins VP, Eberhart C, et al: International Society Of Neuropathology - Haarlem: International Society Of Neuropathology - Haarlem consensus guidelines for nervous system tumor classification and grading. Brain Phatol. 24:429–435. 2014. View Article : Google Scholar
5	Brodbelt A, Greenberg D, Winters T, Williams M, Vernon S and Collins VP; (UK) National Cancer Information Network Brain Tumour Group: Glioblastoma in England: 2007–2011. Eur J Cancer. 51:533–542. 2015. View Article : Google Scholar : PubMed/NCBI
6	Omuro A and DeAngelis LM: Glioblastoma and other malignant gliomas: A clinical review. JAMA. 310:1842–1850. 2013. View Article : Google Scholar : PubMed/NCBI
7	Konovalov AN, Potapov AA, Loshakov VA, Oliushin VE, Kornienko VN, Iartsev VV, Pronin IN, Korshunov AG, Golanov AV, Kobiakov GL, et al: Standards, guidelines, and options in the treatment of glial tumors of the brain in adults. Zh Vopr Neirokhir Im NN Burdenko. 2:3–11. 2006.In Russian.
8	Xhumari A, Rroji A, Enesi E, Bushati T, Sallabanda Diaz K and Petrela M: Glioblastoma after AVM radiosurgery. Case report and review of the literature. Acta Neurochir. 157:889–895. 2015. View Article : Google Scholar : PubMed/NCBI
9	Greto D, Livi L, Bonomo P, Masi L, Detti B, Meattini I, Mangoni M, Doro R, Favuzza V, Cipressi S, et al: Cyberknife stereotactic radiosurgery for the re-irradiation of brain lesions: A single-centre experience. Radiol Med. 119:721–726. 2014. View Article : Google Scholar : PubMed/NCBI
10	Tsao MN, Mehta MP, Whelan TJ, Morris DE, Hayman JA, Flickinger JC, Mills M, Rogers CL and Souhami L: The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for malignant glioma. Int J Radiat Oncol Biol Phys. 63:47–55. 2005. View Article : Google Scholar : PubMed/NCBI
11	Freund D, Zhang R, Sanders M and Newhauser W: Predictive risk of radiation induced cerebral necrosis in pediatric brain cancer patients after VMAT versus proton therapy. Cancers. 7:617–630. 2015. View Article : Google Scholar : PubMed/NCBI
12	Kamiya-Matsuoka C and Gilbert MR: Treating recurrent glioblastoma: An update. CNS Oncol. 4:91–104. 2015. View Article : Google Scholar : PubMed/NCBI
13	Dincoglan F, Beyzadeoglu M, Sager O, Demiral S, Gamsiz H, Uysal B, Ebruli C, Akin M, Oysul K, Sirin S, et al: Management of patients with recurrent glioblastoma using hypofractionated stereotactic radiotherapy. Tumori. 101:179–184. 2015. View Article : Google Scholar : PubMed/NCBI
14	Kickingereder P, Hamisch C, Suchorska B, Galldiks N, Visser-Vandewalle V, Goldbrunner R, Kocher M, Treuer H, Voges J and Ruge MI: Low-dose rate stereotactic iodine-125 brachytherapy for the treatment of inoperable primary and recurrent glioblastoma: Single-center experience with 201 cases. J Neurooncol. 120:615–623. 2014. View Article : Google Scholar : PubMed/NCBI
15	Wang B, Tanaka K, Ji B, Ono M, Fang Y, Ninomiya Y, Maruyama K, Izumi-Nakajima N, Begum N, Higuchi M, et al: Total body 100-mGy X-irradiation does not induce Alzheimer's disease-like pathogenesis or memory impairment in mice. J Radiat Res. 55:84–96. 2014. View Article : Google Scholar :
16	Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups: National Cancer Institute of Canada Clinical Trials Group: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
17	Taal W, Bromberg JE and van den Bent MJ: Chemotherapy in glioma. CNS Oncol. 4:179–192. 2015. View Article : Google Scholar : PubMed/NCBI
18	Zorzan M, Giordan E, Redaelli M, Caretta A and Mucignat-Caretta C: Molecular targets in glioblastoma. Future Oncol. 11:1407–1420. 2015. View Article : Google Scholar : PubMed/NCBI
19	Deutsch MB, Panageas KS, Lassman AB and Deangelis LM: Steroid management in newly diagnosed glioblastoma. J Neurooncol. 113:111–116. 2013. View Article : Google Scholar : PubMed/NCBI
20	Ghiaseddin A and Peters KB: Use of bevacizumab in recurrent glioblastoma. CNS Oncol. 4:157–169. 2015. View Article : Google Scholar : PubMed/NCBI
21	Bryukhovetskyi IS, Bryukhovetskyi AS, Kumeiko VV, Mischenko PV and Khotimchenko YS: Stem cells in carcinogenesis of glioblastoma multiforme. Cell Transplant Tissue Eng. 8:13–19. 2013.
22	Chen D: Tumor formation and drug resistance properties of human glioblastoma side population cells. Mol Med Rep. 11:4309–4314. 2015.PubMed/NCBI
23	Liu Y, Zhang X, Liu J, Hou G, Zhang S and Zhang J: Everolimus in combination with letrozole inhibit human breast cancer MCF-7/Aro stem cells via PI3K/mTOR pathway: An experimental study. Tumour Biol. 35:1275–1286. 2014. View Article : Google Scholar
24	Li C, Lee CJ and Simeone DM: Identification of human pancreatic cancer stem cells. Methods Mol Biol. 568:161–173. 2009. View Article : Google Scholar : PubMed/NCBI
25	Duesberg P, Mandrioli D, McCormack A and Nicholson JM: Is carcinogenesis a form of speciation? Cell Cycle. 10:2100–2114. 2011. View Article : Google Scholar : PubMed/NCBI
26	Altman J: Are new neurons formed in the brains of adult mammals? Science. 135:1127–1128. 1962. View Article : Google Scholar : PubMed/NCBI
27	Lepousez G, Nissant A and Lledo PM: Adult neurogenesis and the future of the rejuvenating brain circuits. Neuron. 86:387–401. 2015. View Article : Google Scholar : PubMed/NCBI
28	Doetsch F, Caillé I, Lim DA, García-Verdugo JM and Alvarez-Buylla A: Subventricular zone astrocytes are neural stem cells in the adult mammalian brain. Cell. 97:703–716. 1999. View Article : Google Scholar : PubMed/NCBI
29	Maldonado-Soto AR, Oakley DH, Wichterle H, Stein J, Doetsch FK and Henderson CE: Stem cells in the nervous system. Am J Phys Med Rehabil. 93(Suppl 3): S132–S144. 2014. View Article : Google Scholar : PubMed/NCBI
30	Zhang S and Cui W: Sox2, a key factor in the regulation of pluripotency and neural differentiation. World J Stem Cells. 6:305–311. 2014. View Article : Google Scholar : PubMed/NCBI
31	Bryukhovetskiy A, Shevchenko V, Kovalev S, Chekhonin V, Baklaushev V, Bryukhovetskiy I and Zhukova M: To the novel paradigm of proteome-based cell therapy of tumors: Through comparative proteome mapping of tumor stem cells and tissuespecific stem cells of humans. Cell Transplant. 23(Suppl 1): S151–S170. 2014. View Article : Google Scholar
32	Vescovi AL, Galli R and Reynolds BA: Brain tumour stem cells. Nat Rev Cancer. 6:425–436. 2006. View Article : Google Scholar : PubMed/NCBI
33	Amendola D, Nardella M, Guglielmi L, Cerquetti L, Carico E, Alesi V, Porru M, Leonetti C, Bearzi C, Rizzi R, et al: Human placenta-derived neurospheres are susceptible to transformation after extensive in vitro expansion. Stem Cell Res Ther. 5(55)2014. View Article : Google Scholar : PubMed/NCBI
34	Wu W, He Q, Li X, Zhang X, Lu A, Ge R, Zhen H, Chang AE, Li Q and Shen L: Long-term cultured human neural stem cells undergo spontaneous transformation to tumor-initiating cells. Int J Biol Sci. 7:892–901. 2011. View Article : Google Scholar : PubMed/NCBI
35	Ilkanizadeh S, Lau J, Huang M, Foster DJ, Wong R, Frantz A, Wang S, Weiss WA and Persson AI: Glial progenitors as targets for transformation in glioma. Adv Cancer Res. 121:1–65. 2014. View Article : Google Scholar : PubMed/NCBI
36	Schichor C, Albrecht V, Korte B, Buchner A, Riesenberg R, Mysliwietz J, Paron I, Motaln H, Turnšek TL, Jürchott K, et al: Mesenchymal stem cells and glioma cells form a structural as well as a functional syncytium in vitro. Exp Neurol. 234:208–219. 2012. View Article : Google Scholar : PubMed/NCBI
37	Wurmser AE and Gage FH: Stem cells: Cell fusion causes confusion. Nature. 416:485–487. 2002. View Article : Google Scholar : PubMed/NCBI
38	Friedmann-Morvinski D: Glioblastoma heterogeneity and cancer cell plasticity. Crit Rev Oncog. 19:327–336. 2014. View Article : Google Scholar : PubMed/NCBI
39	Rahman M, Reyner K, Deleyrolle L, Millette S, Azari H, Day BW, Stringer BW, Boyd AW, Johns TG, Blot V, et al: Neurosphere and adherent culture conditions are equivalent for malignant glioma stem cell lines. Anat Cell Biol. 48:25–35. 2015. View Article : Google Scholar : PubMed/NCBI
40	Fine HA: New strategies in glioblastoma: Exploiting the new biology. Clin Cancer Res. 21:1984–1988. 2015. View Article : Google Scholar : PubMed/NCBI
41	Pavon LF, Marti LC, Sibov TT, Malheiros SM, Brandt RA, Cavalheiro S and Gamarra LF: In vitro analysis of neurospheres derived from glioblastoma primary culture: A novel methodology paradigm. Front Neurol. 4(214)2014. View Article : Google Scholar : PubMed/NCBI
42	Golebiewska A, Bougnaud S, Stieber D, Brons NH, Vallar L, Hertel F, Klink B, Schröck E, Bjerkvig R and Niclou SP: Side population in human glioblastoma is non-tumorigenic and characterizes brain endothelial cells. Brain. 136:1462–1475. 2013. View Article : Google Scholar : PubMed/NCBI
43	Shen G, Shen F, Shi Z, Liu W, Hu W, Zheng X, Wen L and Yang X: Identification of cancer stem-like cells in the C6 glioma cell line and the limitation of current identification methods. In Vitro Cell Dev Biol Anim. 44:280–289. 2008. View Article : Google Scholar : PubMed/NCBI
44	Neradil J and Veselska R: Nestin as a marker of cancer stem cells. Cancer Sci. 106:803–811. 2015. View Article : Google Scholar : PubMed/NCBI
45	Piccirillo SG, Binda E, Fiocco R, Vescovi AL and Shah K: Brain cancer stem cells. J Mol Med Berl. 87:1087–1095. 2009. View Article : Google Scholar : PubMed/NCBI
46	Chen R, Nishimura MC, Bumbaca SM, Kharbanda S, Forrest WF, Kasman IM, Greve JM, Soriano RH, Gilmour LL, Rivers CS, et al: A hierarchy of self-renewing tumor-initiating cell types in glioblastoma. Cancer Cell. 17:362–375. 2010. View Article : Google Scholar : PubMed/NCBI
47	Barrett LE, Granot Z, Coker C, Iavarone A, Hambardzumyan D, Holland EC, Nam HS and Benezra R: Self-renewal does not predict tumor growth potential in mouse models of high-grade glioma. Cancer Cell. 21:11–24. 2012. View Article : Google Scholar : PubMed/NCBI
48	Huang Z, Cheng L, Guryanova OA, Wu Q and Bao S: Cancer stem cells in glioblastoma - molecular signaling and therapeutic targeting. Protein Cell. 1:638–655. 2010. View Article : Google Scholar
49	Bryukhovetskii IS, Bryukhovetskii AS and Khotimchenko YS: New biomolecular approaches to the treatment of glioblastoma multiforme. Bull Exp Biol Med. 158:794–799. 2015. View Article : Google Scholar : PubMed/NCBI
50	Bryukhovetskiy IS, Bryukhovetskiy AS, Mischenko PV and Khotimchenko YS: The role of systemic migration and homing mechanisms of stem cells in the development of malignant tumors of the central nervous system and the development of new cancer therapies. Russian Biotherapeutic J. 4:3–12. 2013.In Russian.
51	Bryukhovetskiy IS, Mischenko PV, Tolok EV, Zaitcev SV, Khotimchenko YS and Bryukhovetskiy AS: Directional migration of adult hematopoeitic progenitors to C6 glioma in vitro. Oncol Lett. 9:1839–1844. 2015.PubMed/NCBI
52	Bryukhovetskiy IS, Bryukhovetskiy AS, Mischenko PV, et al: Migration of human hematopoietic stem cells to cells of glioblastoma line U87 in vitro. Russ Biotherapeutic J. 4:31–36. 2014.
53	Kang R, Zhang Q, Zeh HJ III, Lotze MT and Tang D: HMGB1 in cancer: Good, bad, or both? Clin Cancer Res. 19:4046–4057. 2013. View Article : Google Scholar : PubMed/NCBI
54	Bordji K, Grandval A, Cuhna-Alves L, Lechapt-Zalcman E and Bernaudin M: Hypoxia-inducible factor-2α (HIF-2α), but not HIF-1α, is essential for hypoxic induction of class III β-tubulin expression in human glioblastoma cells. FEBS J. 281:5220–5236. 2014. View Article : Google Scholar : PubMed/NCBI
55	Moore XL, Lu J, Sun L, Zhu CJ, Tan P and Wong MC: Endothelial progenitor cells' 'homing' specificity to brain tumors. Gene Ther. 11:811–818. 2004. View Article : Google Scholar : PubMed/NCBI
56	Rolando C, Parolisi R, Boda E, Schwab ME, Rossi F and Buffo A: Distinct roles of Nogo-a and Nogo receptor 1 in the homeostatic regulation of adult neural stem cell function and neuroblast migration. J Neurosci. 32:17788–17799. 2012. View Article : Google Scholar : PubMed/NCBI
57	Aboody KS, Brown A, Rainov NG, Bower KA, Liu S, Yang W, Small JE, Herrlinger U, Ourednik V, Black PM, et al: Neural stem cells display extensive tropism for pathology in adult brain: Evidence from intracranial gliomas. Proc Natl Acad Sci USA. 97:12846–12851. 2000. View Article : Google Scholar : PubMed/NCBI
58	Aboody KS, Najbauer J, Metz MZ, D'Apuzzo M, Gutova M, Annala AJ, Synold TW, Couture LA, Blanchard S, Moats RA, et al: Neural stem cell-mediated enzyme/prodrug therapy for glioma: Preclinical studies. Sci Transl Med. 5:184ra592013.PubMed/NCBI
59	Schnarr K, Mooney R, Weng Y, Zhao D, Garcia E, Armstrong B, Annala AJ, Kim SU, Aboody KS and Berlin JM: Gold nanoparticle-loaded neural stem cells for photothermal ablation of cancer. Adv Healthc Mater. 2:976–982. 2013. View Article : Google Scholar : PubMed/NCBI
60	Ahmed AU, Thaci B, Alexiades NG, Han Y, Qian S, Liu F, Balyasnikova IV, Ulasov IY, Aboody KS and Lesniak MS: Neural stem cell-based cell carriers enhance therapeutic efficacy of an oncolytic adenovirus in an orthotopic mouse model of human glioblastoma. Mol Ther. 19:1714–1726. 2011. View Article : Google Scholar : PubMed/NCBI
61	Chekhonin VI, Bryukhovetskiy AS, Semenova AB, Ukhova OV and Pavlov KA: The antitumor agent based immunoliposomalnoy biological construction, its production method and vector delivery to the central nervous system with the malignancy. RF Patent 2336901. Filed August 10, 2007; issued October 27, 2008.
62	Intercellular interactions. 2nd edition. revised and supplemented. Meditsina Publishers; Moscow: pp. p2882003
63	Yang AP, Tang LT and Chen JM: Inhibitory effect of bone marrow mesenchymal stem cells on lymphoma cell proliferation. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 22:1610–1615. 2014.In Chinese. PubMed/NCBI
64	Wang M, Cai J, Huang F, Zhu M, Zhang Q, Yang T, Zhang X, Qian H and Xu W: Pre-treatment of human umbilical cordderived mesenchymal stem cells with interleukin-6 abolishes their growth-promoting effect on gastric cancer cells. Int J Mol Med. 35:367–375. 2015.
65	Ahn JO, Chae JS, Coh YR, Jung WS, Lee HW, Shin IS, Kang SK and Youn HY: Human adipose tissue-derived mesenchymal stem cells inhibit T-cell lymphoma growth in vitro and in vivo. Anticancer Res. 34:4839–4847. 2014.PubMed/NCBI
66	Bryukhovetskiy IS, Mischenko PV, Tolok EV, et al: Interaction of hematopoietic stem cells and tumor cells in vitro. Pa Med J. 58:31–37. 2014.In Russian.
67	He X, Li B, Shao Y, Zhao N, Hsu Y, Zhang Z and Zhu L: Cell fusion between gastric epithelial cells and mesenchymal stem cells results in epithelial-to-mesenchymal transition and malignant transformation. BMC Cancer. 15(24)2015. View Article : Google Scholar
68	Sumi S and Yanai G: Fusion of mesenchymal stem cells and islet cells for cell therapy. Methods Mol Biol. 1313:107–113. 2015. View Article : Google Scholar : PubMed/NCBI
69	Aguilar PS, Baylies MK, Fleissner A, Helming L, Inoue N, Podbilewicz B, Wang H and Wong M: Genetic basis of cell-cell fusion mechanisms. Trends Genet. 29:427–437. 2013. View Article : Google Scholar : PubMed/NCBI
70	Willkomm L and Bloch W: State of the art in cell-cell fusion. Methods Mol Biol. 1313:1–19. 2015. View Article : Google Scholar : PubMed/NCBI
71	Fatima A, Hescheler J and Šaric T: Chromosome tracking in fused cells by single nucleotide polymorphisms. Methods Mol Biol. 1313:95–106. 2015. View Article : Google Scholar : PubMed/NCBI
72	Bagci-Onder T, Du W, Figueiredo JL, Martinez-Quintanilla J and Shah K: Targeting breast to brain metastatic tumours with death receptor ligand expressing therapeutic stem cells. Brain. 138:1710–1721. 2015. View Article : Google Scholar : PubMed/NCBI
73	Ezzelarab M, Ezzelarab C, Wilhite T, Kumar G, Hara H, Ayares D and Cooper DK: Genetically-modified pig mesenchymal stromal cells: Xenoantigenicity and effect on human T-cell xenoresponses. Xenotransplantation. 18:183–195. 2011. View Article : Google Scholar : PubMed/NCBI
74	He HL, Liu L, Chen QH, Cai SX, Han JB, Hu SL, Chun P, Yang Y, Guo FM, Huang YZ, et al: MSCs modified with ACE2 restore endothelial function following LPS challenge by inhibiting the activation of RAS. J Cell Physiol. 230:691–701. 2015. View Article : Google Scholar
75	Sainathan SK, Hanna EM, Gong Q, Bishnupuri KS, Luo Q, Colonna M, White FV, Croze E, Houchen C, Anant S, et al: Granulocyte macrophage colony-stimulating factor ameliorates DSS-induced experimental colitis. Inflamm Bowel Dis. 14:88–99. 2008. View Article : Google Scholar
76	Najafi M, Fardid R, Hadadi G and Fardid M: The mechanisms of radiation-induced bystander effect. J Biomed Phys Eng. 4:163–172. 2014.
77	Marín A, Martín M, Liñán O, Alvarenga F, López M, Fernández L, Büchser D and Cerezo L: Bystander effects and radiotherapy. Rep Pract Oncol Radiother. 20:12–21. 2015. View Article : Google Scholar
78	Xiao L, Liu W, Li J, Xie Y, He M, Fu J, Jin W and Shao C: Irradiated U937 cells trigger inflammatory bystander responses in human umbilical vein endothelial cells through the p38 pathway. Radiat Res. 182:111–121. 2014. View Article : Google Scholar : PubMed/NCBI
79	Barani IJ and Larson DA: Radiation therapy of glioblastoma. Cancer Treat Res. 163:49–73. 2015. View Article : Google Scholar
80	Dolecek TA, Propp JM, Stroup NE and Kruchko C: CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in United States in 2005–2009. Neuro Oncol. 14(Suppl 5): v1–v49. 2012. View Article : Google Scholar :
81	Friedmann-Morvinski D: Glioblastoma heterogeneity and cancer cell plasticity. Crit Rev Oncog. 19:327–336. 2014. View Article : Google Scholar : PubMed/NCBI
82	Labussière M, Boisselier B, Mokhtari K, Di Stefano AL, Rahimian A, Rossetto M, Ciccarino P, Saulnier O, Paterra R, Marie Y, et al: Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes. Neurology. 83:1200–1206. 2014. View Article : Google Scholar : PubMed/NCBI
83	Lee JK, Joo KM, Lee J, Yoon Y and Nam DH: Targeting the epithelial to mesenchymal transition in glioblastoma: The emerging role of MET signaling. Onco Targets Ther. 7:1933–1944. 2014.PubMed/NCBI
84	Lassen U, Sorensen M, Gaziel TB, Hasselbalch B and Poulsen HS: Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme. Anticancer Res. 33:1657–1660. 2013.PubMed/NCBI
85	Chinnaiyan P, Won M, Wen PY, Rojiani AM, Wendland M, Dipetrillo TA, Corn BW and Mehta MP: RTOG 0913: A phase 1 study of daily everolimus (RAD001) in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma. Int J Radiat Oncol Biol Phys. 86:880–884. 2013. View Article : Google Scholar : PubMed/NCBI
86	Venkatesh HS, Chaumeil MM, Ward CS, Haas-Kogan DA, James CD and Ronen SM: Reduced phosphocholine and hyperpolarized lactate provide magnetic resonance biomarkers of PI3K/Akt/mTOR inhibition in glioblastoma. Neuro Oncol. 14:315–325. 2012. View Article : Google Scholar :
87	Gardner LB, Li Q, Park MS, Flanagan WM, Semenza GL and Dang CV: Hypoxia inhibits G₁/S transition through regulation of p27 expression. J Biol Chem. 276:7919–7926. 2001. View Article : Google Scholar
88	Goda N, Ryan HE, Khadivi B, McNulty W and Rickert RC: Hypoxia-inducible factor 1alpha is essential for cell cycle arrest during hypoxia. Mol Cell Biol. 23:359–369. 2003. View Article : Google Scholar :
89	Mjelle R, Hegre SA, Aas PA, Slupphaug G, Drabløs F, Saetrom P and Krokan HE: Cell cycle regulation of human DN A repair and chromatin remodeling genes. DNA Repair. 30:53–67. 2015. View Article : Google Scholar
90	Justus CR and Yang LV: GPR4 decreases B16F10 melanoma cell spreading and regulates focal adhesion dynamics through the G₁₃/Rho signaling pathway. Exp Cell Res. 334:100–113. 2015. View Article : Google Scholar : PubMed/NCBI
91	Xiang L, Chi T, Tang Q, Yang X, Ou M, Chen X, Yu X, Chen J, Ho RJ, Shao J, et al: A pentacyclic triterpene natural product, ursolic acid and its prodrug US597 inhibit targets within cell adhesion pathway and prevent cancer metastasis. Oncotarget. 6:9295–9312. 2015. View Article : Google Scholar : PubMed/NCBI
92	Bryukhovetskiy AS, Bryukhovetskiy IS, Shevchenko VE and Davidov MI: Antitumor individual proteome-based effective targeted cell preparation method for its preparation and using of this drug for the treatment of cancer and other malignancies. RF Patent 2335972. Filed December 24, 2012; issued October 20, 2014.